These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 19500152

  • 1. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
    Serebruany VL.
    Fundam Clin Pharmacol; 2009 Aug; 23(4):411-7. PubMed ID: 19500152
    [Abstract] [Full Text] [Related]

  • 2. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2008 May 27; 51(21):2028-33. PubMed ID: 18498956
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L.
    Eur Heart J; 2006 May 27; 27(10):1166-73. PubMed ID: 16621870
    [Abstract] [Full Text] [Related]

  • 7. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG, Naganuma H, Lachno DR, Winters KJ.
    J Cardiovasc Pharmacol; 2007 Mar 27; 49(3):167-73. PubMed ID: 17414229
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators.
    Circulation; 2008 Oct 14; 118(16):1626-36. PubMed ID: 18757948
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
    Serebruany V.
    Thromb Haemost; 2010 Feb 14; 103(2):415-8. PubMed ID: 20126838
    [Abstract] [Full Text] [Related]

  • 12. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
    Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ.
    J Am Coll Cardiol; 2012 Jun 19; 59(25):2338-43. PubMed ID: 22698488
    [Abstract] [Full Text] [Related]

  • 13. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y, Sugidachi A, Ogawa T, Jakubowski JA, Hashimoto M, Isobe T, Otsuguro K, Asai F.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):276-82. PubMed ID: 17996866
    [Abstract] [Full Text] [Related]

  • 14. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK.
    Consult Pharm; 2010 Apr 28; 25(4):241-57. PubMed ID: 20511177
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
    Serebruany VL, Cherepanov V, Cabrera-Fuentes HA, Kim MH.
    Thromb Haemost; 2015 Nov 25; 114(6):1104-12. PubMed ID: 26559427
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
    Serebruany VL.
    Cardiology; 2008 Nov 25; 111(4):265-7. PubMed ID: 18434736
    [No Abstract] [Full Text] [Related]

  • 20. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P, Ferreiro JL, Angiolillo DJ.
    Expert Rev Cardiovasc Ther; 2009 Apr 25; 7(4):361-9. PubMed ID: 19379060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.